Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno‐Safety Technical Committee (ITC)Mineo Matsumoto, Jean G. Sathish, Suresh Kumar Swaminathan et al.|Clinical Pharmacology & Therapeutics|2024Cited by 15
Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitroMarie Fortin, D. Manca|Scientific Reports|2023Cited by 10